281 related articles for article (PubMed ID: 27259241)
1. Comparative evaluation of three proliferation markers, Ki-67, TOP2A, and RacGAP1, in bronchopulmonary neuroendocrine neoplasms: Issues and prospects.
Neubauer E; Wirtz RM; Kaemmerer D; Athelogou M; Schmidt L; Sänger J; Lupp A
Oncotarget; 2016 Jul; 7(27):41959-41973. PubMed ID: 27259241
[TBL] [Abstract][Full Text] [Related]
2. ERCC1 and Ki67 in small cell lung carcinoma and other neuroendocrine tumors of the lung: distribution and impact on survival.
Skov BG; Holm B; Erreboe A; Skov T; Mellemgaard A
J Thorac Oncol; 2010 Apr; 5(4):453-9. PubMed ID: 20104194
[TBL] [Abstract][Full Text] [Related]
3. Validity of the proliferation markers Ki67, TOP2A, and RacGAP1 in molecular subgroups of breast cancer.
Milde-Langosch K; Karn T; Müller V; Witzel I; Rody A; Schmidt M; Wirtz RM
Breast Cancer Res Treat; 2013 Jan; 137(1):57-67. PubMed ID: 23135572
[TBL] [Abstract][Full Text] [Related]
4. Automated quantification of Ki-67 proliferative index of excised neuroendocrine tumors of the lung.
Liu SZ; Staats PN; Goicochea L; Alexiev BA; Shah N; Dixon R; Burke AP
Diagn Pathol; 2014 Oct; 9():174. PubMed ID: 25318848
[TBL] [Abstract][Full Text] [Related]
5. Bronchopulmonary neuroendocrine tumors.
Gustafsson BI; Kidd M; Chan A; Malfertheiner MV; Modlin IM
Cancer; 2008 Jul; 113(1):5-21. PubMed ID: 18473355
[TBL] [Abstract][Full Text] [Related]
6. Molecular markers help characterize neuroendocrine lung tumors.
Rusch VW; Klimstra DS; Venkatraman ES
Ann Thorac Surg; 1996 Sep; 62(3):798-809; discussion 809-10. PubMed ID: 8784011
[TBL] [Abstract][Full Text] [Related]
7. Somatostatin receptors in bronchopulmonary neuroendocrine neoplasms: new diagnostic, prognostic, and therapeutic markers.
Kaemmerer D; Specht E; Sänger J; Wirtz RM; Sayeg M; Schulz S; Lupp A
J Clin Endocrinol Metab; 2015 Mar; 100(3):831-40. PubMed ID: 25494861
[TBL] [Abstract][Full Text] [Related]
8. Downregulation of drs tumor suppressor gene in highly malignant human pulmonary neuroendocrine tumors.
Shimakage M; Kodama K; Kawahara K; Kim CJ; Ikeda Y; Yutsudo M; Inoue H
Oncol Rep; 2009 Jun; 21(6):1367-72. PubMed ID: 19424611
[TBL] [Abstract][Full Text] [Related]
9. Ki-67 antigen in lung neuroendocrine tumors: unraveling a role in clinical practice.
Pelosi G; Rindi G; Travis WD; Papotti M
J Thorac Oncol; 2014 Mar; 9(3):273-84. PubMed ID: 24518085
[TBL] [Abstract][Full Text] [Related]
10. Comparative proteomics of pulmonary tumors with neuroendocrine differentiation.
Cho NH; Koh ES; Lee DW; Kim H; Choi YP; Cho SH; Kim DS
J Proteome Res; 2006 Mar; 5(3):643-50. PubMed ID: 16512680
[TBL] [Abstract][Full Text] [Related]
11. Differential expression and prognostic value of the chemokine receptor CXCR4 in bronchopulmonary neuroendocrine neoplasms.
Kaemmerer D; Reimann C; Specht E; Wirtz RM; Sayeg M; Baum RP; Schulz S; Lupp A
Oncotarget; 2015 Feb; 6(5):3346-58. PubMed ID: 25671300
[TBL] [Abstract][Full Text] [Related]
12. Typical and atypical carcinoid tumors of the lung are characterized by 11q deletions as detected by comparative genomic hybridization.
Walch AK; Zitzelsberger HF; Aubele MM; Mattis AE; Bauchinger M; Candidus S; Präuer HW; Werner M; Höfler H
Am J Pathol; 1998 Oct; 153(4):1089-98. PubMed ID: 9777940
[TBL] [Abstract][Full Text] [Related]
13. The Contrasting Role of p16Ink4A Patterns of Expression in Neuroendocrine and Non-Neuroendocrine Lung Tumors: A Comprehensive Analysis with Clinicopathologic and Molecular Correlations.
Fusco N; Guerini-Rocco E; Del Gobbo A; Franco R; Zito-Marino F; Vaira V; Bulfamante G; Ercoli G; Nosotti M; Palleschi A; Bosari S; Ferrero S
PLoS One; 2015; 10(12):e0144923. PubMed ID: 26674347
[TBL] [Abstract][Full Text] [Related]
14. Advances in neuroendocrine lung tumors.
Travis WD
Ann Oncol; 2010 Oct; 21 Suppl 7():vii65-71. PubMed ID: 20943645
[TBL] [Abstract][Full Text] [Related]
15. [Expression and clinicopathologic significance of human achaete-scute homolog 1 in pulmonary neuroendocrine tumors].
Li F; Zhong Z; Li R; Huang H; Wang L; Zheng D; Zhang D
Zhongguo Fei Ai Za Zhi; 2010 Apr; 13(4):317-21. PubMed ID: 20677557
[TBL] [Abstract][Full Text] [Related]
16. Unbalanced chromosomal aberrations in neuroendocrine lung tumors as detected by comparative genomic hybridization.
Ullmann R; Schwendel A; Klemen H; Wolf G; Petersen I; Popper HH
Hum Pathol; 1998 Oct; 29(10):1145-9. PubMed ID: 9781656
[TBL] [Abstract][Full Text] [Related]
17. Gene product immunophenotyping of neuroendocrine lung tumors. No linking evidence between carcinoids and small-cell lung carcinomas suggested by multivariate statistical analysis.
Sampietro G; Tomasic G; Collini P; Biganzoli E; Boracchi P; Bidoli P; Pilotti S
Appl Immunohistochem Mol Morphol; 2000 Mar; 8(1):49-56. PubMed ID: 10937049
[TBL] [Abstract][Full Text] [Related]
18. Divergent cyclin B1 expression and Rb/p16/cyclin D1 pathway aberrations among pulmonary neuroendocrine tumors.
Igarashi T; Jiang SX; Kameya T; Asamura H; Sato Y; Nagai K; Okayasu I
Mod Pathol; 2004 Oct; 17(10):1259-67. PubMed ID: 15154011
[TBL] [Abstract][Full Text] [Related]
19. Expression of L-type amino acid transporter 1 (LAT1) in neuroendocrine tumors of the lung.
Kaira K; Oriuchi N; Imai H; Shimizu K; Yanagitani N; Sunaga N; Hisada T; Kawashima O; Iijima H; Ishizuka T; Kanai Y; Endou H; Nakajima T; Mori M
Pathol Res Pract; 2008; 204(8):553-61. PubMed ID: 18440724
[TBL] [Abstract][Full Text] [Related]
20. Cellular expression of interleukin 2 (IL-2) and its receptor (IL-2R, CD25) in lung tumours.
Kasprzak A; Olejniczak K; Przybyszewska W; Zabel M
Folia Morphol (Warsz); 2007 Aug; 66(3):159-66. PubMed ID: 17985312
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
